Market Snapshot

BSE Sensex: 77094.07 0.38%
BSE 500: 36342.26 0.46%
BSE 200: 11292.97 0.41%
BSE 100: 25684.81 0.39%
BSE BANKEX: 65360.45 0.44%
BSE IT: 27014.52 0.69%
Nifty 50: 24102.9 0.37%
Nifty 500: 23261.85 0.51%
Nifty 200: 13975.2 0.46%
Nifty 100: 25209.55 0.49%
Nifty Midcap 100: 62729.1 0.34%
Nifty Small 100: 18897 0.60%
Nifty IT: 27628.55 0.74%
Nifty PSU Bank: 8763.9 0.54%

News:

L&T?s arm Vyoma.AI incorporate...
Brahmaputra Infra rises after ...
Asian Energy rises after baggi...
Metropolis Healthcare Ltd lead...
Hybrid Financial Services Ltd ...

Sakar Healthcare Ltd Share Price – NSE
Pharmaceuticals, Small Cap

Invest

22 Jun 2026 | 04:14 PM

818.75

15.15 (1.89%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

127.78%

Return (1Y)

Beaten Nifty 50 by 131.26%
More Volatile

3.16%

Standard Deviation (1Y)

Higher than Nifty 50 by 2.34%
Consistent Performer

7/12

Months

beaten Nifty 50
AxisDirect View

No View

52 Week High-Low

890

311

News & Announcements

Sakar Healthcare jumps after Gautam Baid-founded fund buys stake via bulk deal
36 days ago

Sakar Healthcare jumps after Gautam Baid-founded fund buys stake via bulk deal

18 - May - 2026 12:00 | 36 days ago

According to the bulk deal data on the NSE , Stellar Wealth Partners India Fund I LP purchased 1.95 lakh shares, representing a 0.88% equity stake, at an average price of Rs 664.58 per share.
Gautam Baid or Stellar Wealth Partners India Fund I LP did not feature in Sakar Healthcare?s shareholding pattern for the quarter ended 31 March 2026. This suggests a fresh stake entry in the current quarter.
Stellar Wealth Partners India Fund I LP is a Delaware-based investment partnership founded by investor Gautam Baid.
Ahmedabad-based Sakar Healthcare is a pharmaceutical manufacturer and exporter specializing in oncology, antibiotics, and general formulations. The company operates world-class, EU-GMP and WHO-GMP certified facilities equipped to manufacture oral solids, injectables, oral liquids, and high-potent oncology products.
On a consolidated basis, Sakar Healthcare's net profit surged 91.32% to Rs 11.02 crore while net sales rose 41.52% to Rs 71.10 crore in Q4 March 2026 over Q4 March 2025.

Powered by Capital Market - Live News

Sakar Healthcare consolidated net profit rises 91.32% in the March 2026 quarter

42 days ago

Sakar Healthcare to hold board meeting
47 days ago

Sakar Healthcare to hold board meeting

07 - May - 2026 12:00 | 47 days ago

Sakar Healthcare will hold a meeting of the Board of Directors of the Company on 12 May 2026.
Sakar Healthcare consolidated net profit rises 126.27% in the December 2025 quarter
138 days ago

Sakar Healthcare consolidated net profit rises 126.27% in the December 2025 quarter

05 - Feb - 2026 12:00 | 138 days ago

Net profit of Sakar Healthcare rose 126.27% to Rs 10.25 crore in the quarter ended December 2025 as against Rs 4.53 crore during the previous quarter ended December 2024. Sales rose 62.00% to Rs 70.34 crore in the quarter ended December 2025 as against Rs 43.42 crore during the previous quarter ended December 2024.

Particulars Quarter Ended
Dec. 2025 Dec. 2024 % Var.

Sales 70.34 43.42 62

OPM % 26.43 27.06 -

PBDT 17.33 10.76 61

PBT 10.95 5.53 98

NP 10.25 4.53 126

Powered by Capital Market - Live News

Price vs Volume

1D
5D
1M
3M
1Y
3Y
5Y
MAX

Stock Trivia

FII shareholding in Sakar Healthcare Ltd has decreased by -4.86% since past 1 Year

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

×

Online trading for clients based in USA and Canada is restricted. You can continue placing orders through mapped dealers offline

OK

vV5.0.0.6-60